Vaxart Inc reports results for the quarter ended in December - Earnings Summary

Vaxart

14/03/2024 21:02

* Vaxart Inc  VXRT.OQ  reported a quarterly adjusted loss
of 12
cents​​ per share for the quarter ended in December, higher than
the same quarter last year, when the company reported EPS of -18
cents.  The mean expectation of three analysts for the quarter
was for a loss of 14 cents per share. Wall Street expected
results to range from -16 cents to -13 cents per share.
    * Revenue rose 14,650% to $3.25 million from a year ago;
analysts
expected $1.25 million. 
    * Vaxart Inc's reported EPS for the quarter was a loss of 12
cents​.
    * The company reported a quarterly loss of $17.38 million.
    * Vaxart Inc shares had risen by 97.3% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 12.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Vaxart Inc is
$5.00 
This summary was machine generated from LSEG data March 14 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.14          -0.12          Beat
 Sep. 30 2023      -0.18          -0.11          Beat
 Jun. 30 2023      -0.18          -0.16          Beat
 Mar. 31 2023      -0.19          -0.19          Met